Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DGX Stock Forecast 2025-2026
$186.95
Current Price
$20.80B
Market Cap
Buy 8
Hold 10
Sell 0
Wall St Analyst Ratings
Distance to DGX Price Targets
+15.0%
To High Target of $215.00
+6.4%
To Median Target of $199.00
-11.2%
To Low Target of $166.00
DGX Price Momentum
+4.2%
1 Week Change
+0.1%
1 Month Change
+16.5%
1 Year Change
+23.9%
Year-to-Date Change
-5.4%
From 52W High of $197.55
+25.7%
From 52W Low of $148.70
📊 TOP ANALYST CALLS
Did DGX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Quest Diagnostics is one of their latest high-conviction picks.
Latest DGX Stock Price Targets & Analyst Predictions
Based on our analysis of 31 Wall Street analysts, DGX has a neutral consensus with a median price target of $199.00 (ranging from $166.00 to $215.00). The overall analyst rating is Buy (7.7/10). Currently trading at $186.95, the median forecast implies a 6.4% upside. This outlook is supported by 8 Buy, 10 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Tycho Peterson at Jefferies, projecting a 15.0% upside. Conversely, the most conservative target is provided by Kevin Caliendo at UBS, suggesting a 11.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DGX Analyst Ratings
8
Buy
10
Hold
0
Sell
DGX Price Target Range
Low
$166.00
Average
$199.00
High
$215.00
Current: $186.95
Latest DGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DGX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 27, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $200.00 |
| Oct 22, 2025 | Barclays | Stephanie Davis | Equal-Weight | Maintains | $195.00 |
| Oct 22, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $205.00 |
| Oct 21, 2025 | Jefferies | Tycho Peterson | Buy | Maintains | $215.00 |
| Oct 21, 2025 | Leerink Partners | Michael Cherny | Outperform | Maintains | $210.00 |
| Oct 17, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $210.00 |
| Oct 17, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $190.00 |
| Oct 8, 2025 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $190.00 |
| Oct 2, 2025 | Barclays | Stephanie Davis | Equal-Weight | Maintains | $190.00 |
| Aug 25, 2025 | Baird | Eric Coldwell | Neutral | Downgrade | $194.00 |
| Jul 23, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $180.00 |
| Jul 23, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $192.00 |
| Jul 23, 2025 | Deutsche Bank | Pito Chickering | Hold | Maintains | $178.00 |
| Jul 22, 2025 | Jefferies | Buy | Maintains | $N/A | |
| Jul 18, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $175.00 |
| May 6, 2025 | JP Morgan | Lisa Gill | Neutral | Maintains | $190.00 |
| Apr 28, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $200.00 |
| Apr 23, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $190.00 |
| Apr 23, 2025 | Barclays | Stephanie Davis | Equal-Weight | Maintains | $185.00 |
| Apr 23, 2025 | Baird | Eric Coldwell | Outperform | Maintains | $194.00 |
Quest Diagnostics Inc. (DGX) Competitors
The following stocks are similar to Quest Diagnostics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DGX
Quest Diagnostics
mkt cap
19.97B
Quest Diagnostics Inc. (DGX) Financial Data
Quest Diagnostics Inc. has a market capitalization of $20.80B with a P/E ratio of 22.0x. The company generates $10.85B in trailing twelve-month revenue with a 8.9% profit margin.
Revenue growth is +13.2% quarter-over-quarter, while maintaining an operating margin of +14.9% and return on equity of +14.4%.
Valuation Metrics
Market Cap
$20.80B
Enterprise Value
$26.93B
P/E Ratio
22.0x
PEG Ratio
2.6x
Price/Sales
1.9x
Growth & Margins
Revenue Growth (YoY)
+13.2%
Gross Margin
+33.7%
Operating Margin
+14.9%
Net Margin
+8.9%
EPS Growth
+8.4%
Financial Health
Cash/Price Ratio
+2.1%
Current Ratio
1.1x
Debt/Equity
86.5x
ROE
+14.4%
ROA
+6.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Quest Diagnostics Inc. (DGX) Business Model
About Quest Diagnostics Inc.
What They Do
Healthcare company specializing in diagnostic information services.
Business Model
Quest Diagnostics generates revenue primarily through its laboratory testing services, which are essential for medical decision-making. By processing a vast number of clinical lab results, the company delivers valuable diagnostic insights to physicians, hospitals, and patients, thereby facilitating effective disease detection and treatment management.
Additional Information
The company serves a significant portion of the U.S. population, reportedly one in three adult Americans, and collaborates with over half of U.S. healthcare providers. Its service offerings include a wide array of tests, from routine blood work to advanced genetic screenings, which positions Quest Diagnostics as a pivotal player in the healthcare sector, enhancing clinical practice and public health decision-making.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
55,000
CEO
Mr. James E. Davis
Country
United States
IPO Year
1996
Website
www.questdiagnostics.comQuest Diagnostics Inc. (DGX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Nov 13, 2025
By Zacks Equity Research
Tale of the Tape
Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Nov 10, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Quest Diagnostics (NYSE: DGX) declared a quarterly cash dividend of $0.80 per share, payable on January 28, 2026, to shareholders on record as of January 13, 2026.
Why It Matters
Quest Diagnostics' dividend declaration signals financial health and commitment to returning value to shareholders, potentially boosting investor confidence and stock demand.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
ADP's board approved a $0.16 increase in its quarterly cash dividend to $6.80 annually, marking the 51st consecutive year of dividend increases.
Why It Matters
ADP's 51st consecutive dividend increase signals strong financial health and commitment to returning value, likely boosting investor confidence and stock appeal.
Source: Forbes
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores provide a method for investors to identify top-rated stocks aligned with their investment style, offering a strategic advantage in stock selection.
Why It Matters
Zacks Style Scores provide a streamlined method for identifying high-potential stocks, aiding investment decisions and potentially enhancing portfolio performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Quest Diagnostics' CFO, Sam Samad, will present on the company's strategy and market trends at Citi's 2025 Global Healthcare Conference on December 2, 2025, at 3:15 p.m. ET.
Why It Matters
Quest Diagnostics' CFO discussing strategy and market trends at a major healthcare conference signals potential insights into the company's future performance, influencing investor sentiment and stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis
19 days ago
Quick Summary
Quest AD-Detect® blood tests show high accuracy in diagnosing Alzheimer's disease pathology, potentially reducing the need for PET imaging confirmation, per a recent study.
Why It Matters
The Quest AD-Detect® tests could significantly lower diagnostic costs and streamline Alzheimer's disease identification, potentially impacting healthcare spending and related stock performance in biotech firms.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Zacks Style Scores help investors identify top-rated stocks aligned with their investing style, providing a useful tool for stock selection.
Why It Matters
The Zacks Style Scores provide a systematic method for identifying high-potential stocks, aiding investors in making informed decisions aligned with their strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About DGX Stock
What is Quest Diagnostics Inc.'s (DGX) stock forecast for 2026?
Based on our analysis of 31 Wall Street analysts, Quest Diagnostics Inc. (DGX) has a median price target of $199.00. The highest price target is $215.00 and the lowest is $166.00.
Is DGX stock a good investment in 2026?
According to current analyst ratings, DGX has 8 Buy ratings, 10 Hold ratings, and 0 Sell ratings. The stock is currently trading at $186.95. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DGX stock?
Wall Street analysts predict DGX stock could reach $199.00 in the next 12 months. This represents a 6.4% increase from the current price of $186.95. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Quest Diagnostics Inc.'s business model?
Quest Diagnostics generates revenue primarily through its laboratory testing services, which are essential for medical decision-making. By processing a vast number of clinical lab results, the company delivers valuable diagnostic insights to physicians, hospitals, and patients, thereby facilitating effective disease detection and treatment management.
What is the highest forecasted price for DGX Quest Diagnostics Inc.?
The highest price target for DGX is $215.00 from Tycho Peterson at Jefferies, which represents a 15.0% increase from the current price of $186.95.
What is the lowest forecasted price for DGX Quest Diagnostics Inc.?
The lowest price target for DGX is $166.00 from Kevin Caliendo at UBS, which represents a -11.2% decrease from the current price of $186.95.
What is the overall DGX consensus from analysts for Quest Diagnostics Inc.?
The overall analyst consensus for DGX is neutral. Out of 31 Wall Street analysts, 8 rate it as Buy, 10 as Hold, and 0 as Sell, with a median price target of $199.00.
How accurate are DGX stock price projections?
Stock price projections, including those for Quest Diagnostics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 15, 2025 10:34 AM UTC